Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals
Recently, two oral-administered peptide pharmaceuticals, semaglutide and octreotide, have been developed and are considered as a breakthrough in peptide and protein drug delivery system development. In 2019, the Food and Drug Administration (FDA) approved an oral dosage form of semaglutide developed...
Main Authors: | Jae Cheon Kim, Eun Ji Park, Dong Hee Na |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/12/1585 |
Similar Items
-
Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C<sub>10</sub>)
by: Caroline Twarog, et al.
Published: (2019-02-01) -
Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC ‐ What is Coming Next?
by: Marilena Bohley, et al.
Published: (2024-09-01) -
An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics
by: Nirnoy Dan, et al.
Published: (2020-12-01) -
Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles
by: Sonal Mehrotra, et al.
Published: (2024-03-01) -
Long‐term daily oral administration of intestinal permeation enhancers is safe and effective in mice
by: Katherine C. Fein, et al.
Published: (2023-01-01)